Ensysce Biosciences, Inc. (ENSC)
ENSCNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.3615
+0.0262 (+7.81%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $6.78m
- P/E
- –
- EPS, last 4 quarters
- $-2.76
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.2300 to $2.17
- Average volume
- 506.9k
- Previous close
- $0.3353
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $2.00, +453.3% from here
Earnings
next estimate $-0.1900Next report Nov 13, 2026
Sep 2025
-51.8%
Dec 2025
+40.5%
Mar 2026
+28.8%
Jun 2026
+60.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $493.0k | $1.88m | $961.0k | $1.16m |
| Gross profit | $493.0k | $1.88m | $961.0k | $1.16m |
| Operating income | -$3.74m | -$2.78m | -$3.56m | -$2.58m |
| Net income | -$3.73m | -$2.77m | -$3.56m | -$2.57m |
Last four quarters: revenue $4.50m, margin -280.5%, free cash flow –
News
8 latest- Ensysce Biosciences, Inc. Announces Leadership Transition Following December 14, 2026 Annual MeetingFintel · 5 days ago
- Cantor Fitzgerald Initiates Coverage of Ensysce Biosciences at OverweightFintel · Oct 20, 2026
- Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66% RTTNews · Aug 6, 2026
- Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down RTTNews · Jul 14, 2026
- Ensyce Reports Extension Of Patent On MPAR To Prevent Opioid Abuse RTTNews · May 19, 2026
- Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 RTTNews · Jan 29, 2026
- Ensysce Biosciences Narrows Loss in Q2The Motley Fool · Aug 13, 2025
- Ensysce focused on clinical development milestones for PF614, PF614-MPARTipRanks · Jan 8, 2025
The company
Ensysce Biosciences is a clinical-stage biotechnology company developing novel neuroplastogenic therapies using psychedelics that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The company is also developing a new class of highly novel opioids for the treatment of severe pain while minimizing the risk of both drug abuse and overdose.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- ensysce.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.